NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Diagnostics & Research · USD

CareDx, Inc. (CDNA) Stock Analysis

CareDx, Inc. (CDNA) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CDNA

$70.74

+$1.54 (+2.23%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CDNA with… →

CDNA Key Statistics

As of Oct 21, 2026
Trading
Open
$69.50
Previous Close
$69.20
Day's Range
68.28–72.71
52-Week Range
14.03–72.51
Volume
1.63M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.38
Valuation
Market Cap
$3.38B
P/E Ratio
31.46
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
50.72
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
7.39
EPS (ttm)Profit attributable to each share over the last twelve months.
2.08
Financials (FY)
Revenue (FY)
$379.81M+13.79%
Net Income (FY)
−$21.35M−140.64%
Profit marginThe share of revenue left as profit after all costs and taxes.
24.23%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
51.73M
1-Year Return
+365.70%
Dividend and dates
Earnings Date
November 3, 2026estimated
Avg Volume
1.31M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CDNA closed at $70.74, +365.70% over 1 year.

CareDx, Inc. (CDNA) has a market capitalization of $3.38B.

In fiscal 2025, CDNA reported revenue of $379.81M.

CDNA Stock Return by Calendar Year

CareDx, Inc. (CDNA) 10-year return: what $10,000 became

1 year
$10,000 $46,570
+365.70%
5 years
$10,000 $9,977
−0.23%
10 years
$10,000 $180,921
+1,709.21%

If you had invested $10,000 in CareDx, Inc. (CDNA) 10 years ago, at the close on October 21, 2016, it would have been worth $180,921 at the close on October 21, 2026: +1,709.21% in total, +33.58% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+275.48%
2025−12.00%
2024+78.42%
2023+5.17%
2022−74.91%
2021−37.23%
2020+235.88%
2019−14.20%
2018+242.51%
2017+171.85%
2016 (partial year)−41.32%

As of October 21, 2026.

CDNA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$379.81M−$21.35M−5.6%
2024$333.79M$52.55M15.7%
2023$280.32M−$190.28M−67.9%
2022$321.79M−$76.61M−23.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$379.81M$256.57M−$25.07M−$21.35M−5.6%
2024$333.79M$224.09M−$55.54M$52.55M15.7%
2023$280.32M$178.26M−$107.06M−$190.28M−67.9%
2022$321.79M$209.58M−$77.23M−$76.61M−23.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CDNA Valuation vs Diagnostics & Research Median

Median of 45 stocks
MetricCDNADiagnostics & Research medianvs median
P/E31.4637.5916% below
P/S ratio7.395.2341% above
Profit margin24.23%−0.93%25.2 pts above

Medians across 45 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

CareDx, Inc. (CDNA) is capitalised at $3.38B on the latest close. It is classified in the Diagnostics & Research industry, within the Healthcare sector. Headcount on file is 761.

The 52-week range on file runs from $14.03 to $72.51. CDNA last closed at $70.74 on October 21, 2026. That is +$1.54 (+2.23%) against the previous close. The latest close sits 404.21% above that 52-week low.

Financial Health

In fiscal 2025, CareDx, Inc. reported revenue of $379.81M. That is +13.79% against the prior fiscal year, when revenue was $333.79M. The same year closed with a net loss of $21.35M. The reported profit margin is 24.23%. That is 25.2 percentage points above the Diagnostics & Research median of −0.93%. Earnings per share on a trailing basis come to 2.08.

Across the 4 fiscal years on file, revenue moves from $321.79M in 2022 to $379.81M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 31.46 times earnings. That is 16.3% below the Diagnostics & Research median of 37.59. The forward P/E on file is 50.72. Measured against sales, the shares trade at 7.39 times revenue. On price-to-sales that is 41.37% above the Diagnostics & Research median of 5.23. The medians here are taken across 45 Diagnostics & Research companies that report the metric.

Over the trailing twelve months the total return is +365.70%. Measured over 10 years, that is +33.58% a year compounded. Beta against the wider market is reported at 2.38. Annualized volatility over the trailing 10 years is 79.04%.

Growth & Income

No dividend is on file for CDNA.

The strongest complete calendar year on file is 2018 at +242.51%; the weakest is 2022 at −74.91%. Of the 9 complete calendar years on file, 5 finished higher. So far in 2026 the total return is +275.48%.

Peer Comparison

CareDx, Inc. (CDNA) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
CareDx, Inc. CDNA $3.38B 31.5
Thermo Fisher Scientific Inc. TMO $256.61B 37.4
Danaher Corporation DHR $164.40B 41.7
Natera, Inc. NTRA $59.59B —

The Diagnostics & Research industry average P/E ratio is 37.6x. CareDx, Inc. trades at a P/E of 31.5.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$256.61B

 DHR

Danaher Corporation

$164.40B

 NTRA

Natera, Inc.

$59.59B

 A

Agilent Technologies, Inc.

$50.12B

 IQV

IQVIA Holdings Inc.

$45.53B

 WAT

Waters Corporation

$44.92B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About CareDx, Inc.

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.

Visit website →